Next Generation Immunotherapies Market Outlook 2025: Mapping Growth, Innovation, and Regional Shifts
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
#What Are the Projected Market Size and Growth Rates for the Next Generation Immunotherapies Market From 2025 To 2029?#_x000D_
The market size of next-generation immunotherapies has seen a swift expansion in the past few years. It is projected to rise from $133.81 billion in 2024 to $150.54 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 12.5%. The notable growth during the historic period could be credited to the increased prevalence of oncology diseases, an escalation in research and development funding, more government initiatives, a surge in government health expenditure, and widened indications._x000D_
_x000D_
The market size of next generation immunotherapies is projected to witness substantial expansion in the upcoming years, reaching $238.04 billion in 2029, with a compound annual growth rate (CAGR) of 12.1%. Factors contributing to this growth during the forecasted period include the escalating incidence of cancer, increased spending on healthcare, wider acceptance of chimeric antigen receptor (CAR) T-cell therapy, growing chronic disease burden and continued investment in next-generation drug research. Key trends for this period are a shift towards combination therapies, technological innovation, new avenues in therapeutic strategies, progressions in personalized medicine, and advancements supported by regulatory bodies._x000D_
_x000D_
#Download a free sample to assess the report’s scope and structure:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=21231&type=smp_x000D_
_x000D_
#What External and Internal Drivers Are Contributing to the Growth of the Next Generation Immunotherapies Market?#_x000D_
The surge in cancer cases is anticipated to stimulate the expansion of the next-generation immunotherapies market. Cancer, a collection of diseases marked by unchecked growth and dissemination of abnormal body cells, is becoming more commonplace due to aging populations, lifestyle modifications, environmental exposures, and better detection techniques. Next-generation immunotherapies represent a step forward in personalized treatments, enhancing the body’s ability to fight cancer with greater effectiveness and longevity. According to data from the National Cancer Institute, a United States government agency, there were nearly 20 million new cancer diagnoses and 9.7 million cancer-related fatalities worldwide in 2022. By 2040, these figures are expected to rise to 29.9 million new cases and 15.3 million deaths. Thus, the escalating cancer rate is a key driver for the growth of the next-generation immunotherapies market._x000D_
_x000D_
#What Segment Types Define the Next Generation Immunotherapies Market Structure?#_x000D_
The next generation immunotherapies market covered in this report is segmented –_x000D_
_x000D_
1) By Drug Class: Monoclonal Antibodies, Antibody-Drug Conjugates – ADC’s, Angiotensin-Converting Enzyme (ACE) Inhibitors, Immune Checkpoint Inhibitors_x000D_
2) By Route Of Administration: Intravenous, Parenteral, Intratumoral, Subcutaneous, Oral_x000D_
3) By Distribution Channel: Hospital Pharmacies, Clinical Pharmacies, Other Distribution channels_x000D_
_x000D_
Subsegments:_x000D_
1) By Monoclonal Antibodies: Anti-PD-1 Antibodies, Anti-PD-L1 Antibodies, Anti-CTLA-4 Antibodies, Anti-CD20 Antibodies, Other Monoclonal Antibodies_x000D_
2) By Antibody-Drug Conjugates (ADC’s): HER2-targeted ADCs, CD30-targeted ADCs, CD19-targeted ADCs, Other ADCs_x000D_
3) By Angiotensin-Converting Enzyme (ACE) Inhibitors: ACE Inhibitors For Cancer Therapy, ACE Inhibitors For Other Indications_x000D_
4) By Immune Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors, CTLA-4 Inhibitors, Other Immune Checkpoint Inhibitors_x000D_
_x000D_
#Request customized data on this market:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=21231&type=smp_x000D_
_x000D_
#Which Geographic Areas Hold the Strongest Growth Potential in the Next Generation Immunotherapies Market?#_x000D_
North America was the largest region in the next-generation immunotherapies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation immunotherapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#What Long-Term Trends Are Transforming the Competitive Landscape of the Next Generation Immunotherapies Market?#_x000D_
Prominent businesses in the next-generation immunotherapies market are zeroing in on the creation of groundbreaking therapies like CAR T-cell therapy, aimed at treating cancers, autoimmune diseases, and infectious diseases. The specific therapy involves the genetic modification of a patient’s T cells (a type of immune cell) to carry chimeric antigen receptors (CARs). To illustrate, Immuneel Therapeutics Private Limited, a cell and gene therapy innovator based in India, initiated Qartemi, the first CAR T-cell therapy in India, in January 2025. This therapy serves adult B-cell non-Hodgkin lymphoma by genetically altering a patient’s immune cells to target and kill cancer cells, providing a highly efficient and individualized treatment method. It offers renewed optimism to patients for whom standard treatments have fallen short, with the added benefit of being more cost-effective than comparable global alternatives._x000D_
_x000D_
#View the full report here:#_x000D_
_x000D_
#What Is the Definition of the Next Generation Immunotherapies Market?#_x000D_
Next-generation immunotherapies refer to advanced treatments designed to enhance the body’s immune system to fight diseases, particularly cancer, with improved precision, efficacy, and safety. These therapies go beyond traditional immune-based treatments by leveraging cutting-edge technologies and aim to overcome earlier immunotherapies’ limitations, reduce side effects, and offer long-lasting immune responses._x000D_
_x000D_
#Purchase the full report and get a swift delivery:#_x000D_
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21231_x000D_
_x000D_
#About The Business Research Company:#_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 3156230293_x000D_
Asia +44 2071930708_x000D_
Europe +44 2071930708_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
